Business Wire

LEO Pharma Announces FDA Approval of Adbry™ (tralokinumab) as the First and Only Treatment Specifically Targeting IL-13 for Adults With Moderate-to-Severe Atopic Dermatitis

Share

LEO Pharma A/S, a global leader in medical dermatology, announced today that the U.S. Food and Drug Administration (FDA) has approved Adbry (tralokinumab) for the treatment of moderate-to-severe atopic dermatitis in adults 18 years or older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Adbry can be used with or without topical corticosteroids.1 Adbry is the first and only FDA approved biologic that specifically binds to and inhibits the IL-13 cytokine, a key driver of atopic dermatitis signs and symptoms.1,2,3

“Today’s FDA approval of Adbry is a major milestone for LEO Pharma and for the millions of people living with moderate-to-severe atopic dermatitis who struggle to find a suitable treatment option for this chronic and debilitating disease,” said Anders Kronborg, Chief Financial Officer and Acting Chief Executive Officer of LEO Pharma A/S. “As our first biologic in the U.S., Adbry signifies important progress in our mission of advancing the standard of care in medical dermatology.”

The approval of Adbry is based on safety and efficacy results from the ECZTRA 1, 2 and ECZTRA 3 pivotal Phase 3 trials, which included nearly 2,000 adult patients with moderate-to-severe atopic dermatitis.1 Safety data was evaluated from a pool of five randomized, double-blind, placebo-controlled trials, including ECZTRA 1, 2 and ECZTRA 3, a dose-finding trial, and a vaccine response trial.1

“Atopic dermatitis can be severe and unpredictable, which makes it not only challenging for patients to achieve long-term disease control, but also for clinicians to treat, since there are limited treatment options for this burdensome chronic skin disease,” said Jonathan Silverberg, MD, PhD, MPH, Associate Professor of Dermatology at George Washington University School of Medicine and Health Sciences, and tralokinumab clinical trial investigator. “Adbry will be an important addition to our therapeutic armamentarium as a treatment designed to specifically target and neutralize the IL-13 cytokine, thereby, helping patients manage their atopic dermatitis.”

Adbry will be available in a 150 mg/mL prefilled syringe for subcutaneous injection with an initial dose of 600 mg followed by 300 mg every other week. Adbry can be used with or without TCS.1 A dosage of 300 mg every four weeks may be considered for patients below 100 kg who achieve clear or almost clear skin after 16 weeks of treatment.1

To help eligible patients have access to Adbry, LEO Pharma will introduce the AdbryTM AdvocateTM Program to support U.S. patients at diagnosis and through treatment with Adbry.

“For people living with atopic dermatitis, the experience goes beyond the skin, often impacting important psychosocial aspects of their life,” said Julie Block, President and CEO of the National Eczema Association. “It’s exciting to see a new, targeted therapeutic option for adult patients living with moderate-to-severe atopic dermatitis. Therapeutic advances like this provide much needed hope for those who may have spent years struggling to find a suitable therapy to alleviate the burden of this disease.”

The FDA approval marks the fifth global regulatory approval for tralokinumab in 2021. Tralokinumab is marketed outside of the U.S. under the tradename Adtralza® and is currently approved in the European Union, Great Britain, Canada and the United Arab Emirates.

About the pivotal ECZTRA 1, 2 and ECZTRA 3 Trials

ECZTRA 1 and ECZTRA 2 (ECZema TRAlokinumab trials Nos. 1 and 2) were randomized, double-blind, placebo-controlled, multinational 52-week trials, which included 802 and 794 adult patients, respectively, to evaluate the efficacy and safety of Adbry (300 mg every other week) as monotherapy in adults with moderate-to-severe atopic dermatitis who were candidates for systemic therapy.4

ECZTRA 3 (ECZema TRAlokinumab trial No. 3) was a double-blind, randomized, placebo-controlled, multinational 32-week trial, which included 380 adult patients, to evaluate the efficacy and safety of Adbry (300 mg every other week) in combination with TCS as needed in adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.5

About atopic dermatitis

Atopic dermatitis is a chronic, inflammatory, skin disease characterized by intense itch and eczematous lesions.6 Atopic dermatitis is the result of skin barrier dysfunction and immune dysregulation, leading to chronic inflammation.7 Type 2 cytokines, including IL-13, play a central role in the key aspects of atopic dermatitis pathophysiology.2

About Adbry (tralokinumab)

Adbry (tralokinumab) is a human monoclonal antibody developed to specifically neutralize the IL-13 cytokine, which plays a key role in the immune and inflammatory processes underlying atopic dermatitis signs and symptoms. Adbry specifically binds to the IL-13 cytokine, thereby inhibiting interaction with the IL-13 receptor α1 and α2 subunits (IL-13Rα1 and IL-13Rα2).2,3

About LEO Pharma

LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries. In 2020, the company generated net sales of DKK 10,133 million. For more information, please visit www.LEO-Pharma.com.

Dr. Silverberg is a paid consultant for LEO Pharma.

References

  1. Adbry™ (tralokinumab) Prescribing Information. LEO Pharma; December 2021.
  2. Bieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020; 75:54-62.
  3. Popovic B, et al.Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Rα1 and IL-13Rα2. J Mol Biol. 2017; 429:208–19.
  4. Wollenberg A, et al. Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021; Mar;184(3):437-449.
  5. Silverberg JI, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021; Mar;184(3):450-463.
  6. Weidinger S, et al. Atopic dermatitis. Lancet. 2016;387:1109-1122.
  7. Boguniewicz M, et al. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev 2011;242(1):233-46.

MAT-45764 December 2021

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

David Patti
LEO Pharma, Global Product Communications
973.796.7706
DAPAI@leo-pharma.com

Pia Beltrão Hansen
LEO Pharma, Director Global Commercial Communications
+45 3140 1245
IRQDK@leo-pharma.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Safeguard Global Acquires Global Upside to Expand Reach and Offerings for Companies Growing and Operating Globally27.1.2022 13:07:00 CET | Press release

Safeguard Global, a global future of work company, announced today its acquisition of Global Upside, a global expansion technology and services company based in San Jose, Calif. The deal expands the company’s ability to help emerging and established multinationals compliantly recruit, hire, pay—and now set up operations—anywhere in the world. The move also helps Safeguard Global continue building out its workforce management technology platform, Global Unity, to be able to provide end-to-end digital service. The acquisition, part of an aggressive growth strategy, combines the momentum of the two hyper-growth companies in an industry that is growing quickly to meet increasing demand for workforce management solutions. It makes Safeguard Global, which founded the Employer of Record (EOR) industry in 2011, the largest EOR in global coverage and breadth of services. It also adds new markets in Latin America, Eastern Europe, Africa and Asia. “The team at Global Upside built an amazing compa

ABB Acquires Controlling Interest in InCharge Energy, Strengthening its EV Charging Solutions in the U.S.27.1.2022 12:00:00 CET | Press release

ABB today announced the acquisition of a controlling stake in electric vehicle (EV) commercial charging infrastructure solutions company InCharge Energy. The addition of InCharge Energy will strengthen ABB’s E-mobility Division in the North American market by broadening its customer base and expanding its fleet electrification software and digital services offering. The transaction is part of ABB E-mobility’s growth strategy and is intended to accelerate the expansion of its portfolio to include turnkey EV infrastructure solutions to private and public commercial fleets, EV manufacturers, ride-share operators, municipalities, and commercial facilities owners. Financial terms of the transaction were not disclosed. InCharge Energy tailors end-to-end EV charging infrastructure solutions, from initial consultancy and recommendations on required energy upgrades to the procurement, installation, operation, and maintenance of charging systems. It also provides cloud-based software services fo

How difficult was the journey of iDenfy?27.1.2022 10:47:00 CET | Press release

iDenfy, which began its journey in 2017 as a Lithuanian startup, takes a look back to share about the company’s early days and the road it took to get to where it is today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220121005320/en/ iDenfy team (Photo: Business Wire) Even though iDenfy started to run in 2017, the idea goes back to 2015. Many industries, especially banking, weren't regulated to the extent they are now. Automated identity verification solutions dominated the marketplace but lacked security. The people behind the company decided to develop a supervised ID verification solution, and the decision remains at the core of the company today. Innovations and adaptations Even though iDenfy’s solution was rather primitive and the company only had three employees, the demand for a more secure verification was there. It allowed the company to secure its first clients and investments. “The marketplace was constantly ch

Ola Announces Futurefoundry27.1.2022 10:00:00 CET | Press release

Ola Electric, India’s leading manufacturer of EVs, today announced Ola Futurefoundry, its global center for advanced engineering and vehicle design. This center will be based in Coventry, UK, a global hub for the best automotive design and engineering talent in the world. Ola Futurefoundry will work in-synch with the design and engineering teams based at Ola Campus in Bangalore, India. It will house global talent across multiple disciplines of 2W and 4W vehicle design, advanced high performance automotive engineering, digital & physical modeling and more. It will also house talent that will focus on vehicle R&D around new energy systems including cell technologies. Ola will invest £100M over the next 5 years into the state of the art center and staff it with over 200 designers and automotive engineers. The centre will also partner with world class education and research institutions in the UK to collaborate on technology research and development. Bhavish Aggarwal, Founder & CEO, Ola sa

Terralpha harnesses ADVA TeraFlex ™ for 600G transport throughout France27.1.2022 09:00:00 CET | Press release

ADVA (FSE: ADV) today announced that Terralpha has deployed its FSP 3000 TeraFlex™ terminal to transport data at speeds up to 600Gbit/s between cities across France. The solution enables Terralpha – the new service provider arm of France’s SNCF railway group – to use its spare fiber capacity to offer low-latency, ultra-high-speed connectivity to customers. Now, enterprises, mobile network operators and government institutions can leverage flexible, highly reliable services for edge computing and 5G applications. What’s more, Terralpha’s network will enable homes and businesses in many underserved areas to access next-generation broadband and mobile connectivity. The new solution also features ADVA’s FSP 3000 OLS, flexgrid multi-degree ROADMs, its ALM fiber monitoring technology and its Ensemble Controller network management and control solution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005706/en/ ADVA’s TeraFlex™

Xsolla Expands Into India With Paytm Payment Gateway to Help Developers Sell Games to the India Market27.1.2022 08:56:00 CET | Press release

Xsolla, the video game business engine that helps developers and publishers launch and operate games globally, today announced it teamed up with Paytm Payment Gateway, India's leading payments solutions provider, to bring gaming payments solutions to India. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126006130/en/ Xsolla expands into India with Paytm payment gateway (Graphic: Business Wire) Xsolla integrated Paytm’s Digital Wallet, Unified Payment Interface (UPI), and online banking payment solutions into its Pay Station platform. Video game developers and publishers can monetize their products in India giving them access to the massive gaming marketplace of more than 400 million gamers, second only to China’s playerbase. “India has become one of the fastest-growing game economies in Asia, bringing in approximately $1.5B annually, with growth expected to nearly triple by 2024,” said Xsolla’s Head of Payments and Commer

2022 SPIE and Photonics Media Prism Awards Celebrate Innovative Photonics Technologies27.1.2022 07:10:00 CET | Press release

Earlier this evening, following a festive reception during SPIE Photonics West, SPIE, the international society for optics and photonics, and Photonics Media recognized the top optics and photonics products on the market with their industry-focused Prism Awards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005964/en/ 2022 SPIE and Photonics Media Prism Awards celebrate innovative photonics technologies at SPIE Photonics West. (Graphic: Business Wire) The 14th annual ceremony showcased a dynamic range of companies — from Luxexcel, PlenOptika, and Lumotive, to SWIR, LightPath Technologies, and ColdQuanta — applying innovative and creative solutions to critical problems in areas such as augmented and virtual reality, biomedical devices, autonomous vehicles, quantum, and industrial lasers. In addition, the 2021 Prism Award winners of last year’s virtual ceremony were recognized in person at the beginning of the program.